Position in EXEL
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$1,240,057
-$346,315 QoQ
Shares Held
22,791
-38.4% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#315
of 751 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Concurrent Investment Advisors, LLC holds $48,406,067 across 42 Biotechnology names. EXEL ranks #8 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
|
306,280 | $11,947,982 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
190,938 | $6,757,295 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
10,145 | $5,039,325 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
90,537 | $4,937,887 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
7,521 | $2,264,046 | |
| 6 | BEAM |
Beam Therapeutics Inc.
|
63,879 | $2,192,326 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,839 | $1,770,229 | |
| 8 | EXEL |
Exelixis, Inc.
This page
|
22,791 | $1,240,057 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,240,057 | 22,791 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $1,586,372 | 36,987 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $1,377,181 | 31,421 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $987,441 | 23,909 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $825,442 | 18,726 | Shares | Sole | 2025-07-25 | |
| 2025-03-31 | $457,143 | 12,382 | Shares | Sole | 2025-04-29 | |
| No filing history on record for this holder in this stock. | ||||||